文献速递免疫规划传染病防控与疫情报告

芬兰婴儿10价肺炎球菌结合疫苗接种对肺炎球菌脑膜炎的长期人群影响

Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland.
PubMed 文献 · Vaccine · 2021-04-30

该研究基于芬兰人群的观察性数据,比较2011-2017年(PCV10期)与2004-2010年(基线期)肺炎球菌脑膜炎(PM)的年龄和血清型别发病率和30天死亡率。结果显示PCV10期总体PM发病率下降27%,PCV10血清型脑膜炎下降68%,PM相关死亡率下降42%;但≥65岁成人中非PCV10血清型增加157%,抵消了PCV10血清型的下降。

要点

  • 婴儿PCV10接种后总体PM发病率下降27%,PCV10血清型PM下降68%。
  • PM相关死亡率下降42%,50-64岁人群病死率从25%降至10%。
  • ≥65岁成人PM负担未变,非PCV10血清型增加157%抵消了PCV10血清型下降。

核心结论

  • 婴儿PCV10接种对疫苗血清型PM及其相关死亡率有显著影响和群体保护。
  • ≥65岁成人因血清型替换,PM负担保持不变。

研究设计与样本

  • 基于人群的观察性研究,比较2011-2017年(PCV10期)与2004-2010年(基线期)的数据。
  • PM病例定义为脑脊液分离出肺炎链球菌,或血液分离出肺炎链球菌且培养阳性日期前后30天内ICD-10出院诊断为细菌性脑膜炎。
  • 使用泊松回归模型比较年龄和血清型别发病率和30天死亡率,绝对率差和95%CI通过delta法计算。

主要发现

  • PCV10期总体PCV10血清型脑膜炎发病率下降68%(95%CI 57%-77%),总体PM发病率下降27%(95%CI 12%-39%)。
  • 0-4岁、50-64岁和≥18岁年龄组总体PM发病率分别下降64%、34%和19%。
  • ≥65岁成人中PCV10血清型下降69%,但非PCV10血清型增加157%(56%-342%)。
  • PM相关总体死亡率下降42%(95%CI 4%-65%)。
  • 总体病死率基线期为16%,PCV10期为12%(p=0.41);50-64岁人群病死率从25%降至10%(p=0.04)。

临床怎么用

  • 婴儿PCV10接种可显著降低儿童和部分成人疫苗血清型PM发病率及相关死亡率。
  • 对≥65岁成人需关注血清型替换导致的持续PM负担,可能需要优化疫苗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No previous studies have reported long-term follow-up of ten-valent pneumococcal conjugate vaccine (PCV10) program impact on pneumococcal meningitis (PM). We assessed the effects of infant PCV10 program on PM incidence, mortality and serotype distribution in children and adults during 7 years after introduction. METHODS: We conducted a population-based observational study. A case of PM was defined as isolation of Streptococcus pneumoniae from cerebrospinal fluid or, a patient with S. pneumoniae isolated from blood and an ICD-10 hospital discharge diagnosis of bacterial meningitis within 30 days before or after positive culture date.We compared age- and serotype-specific incidence and associated 30-day mortality rates in 2011-2017 (PCV10 period) with those in 2004-2010 (pre-PCV10 baseline) by using Poisson regression models. Absolute rate differences and 95% confidence intervals (CIs) were calculated from the parameter estimates by using delta method. RESULTS: During the PCV10 period, the overall incidence of PCV10 serotype meningitis decreased by 68% (95%CI 57%-77%), and the overall PM incidence by 27% (95%CI: 12%-39%). In age groups 0-4, 50-64, and ≥ 18 years, the overall PM incidence was reduced by 64%, 34% and 19%, respectively. In adults ≥ 65 years of age, a 69% reduction in PCV10 serotypes was offset by 157% (56%-342%) increase in non-PCV10 serotypes. The overall PM-related mortality rate decreased by 42% (95%CI 4%-65%). Overall case fatality proportion (CFP) was 16% in pre-PCV10 period and 12% in PCV10 period (p = 0.41); among persons 50-64 years the CFP decreased from 25% to 10% (p = 0.04). CONCLUSIONS: We observed substantial impact and herd protection for vaccine-serotype PM and associated mortality after infant PCV10 introduction. However, in older adults ≥ 65 years of age, PM burden remains unchanged due to serotype replacement.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Polkowska A, Rinta-Kokko H, Toropainen M, et al. Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland. Vaccine. 2021. PMID: 33934915. doi:10.1016/j.vaccine.2021.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。